厄洛替尼对EGFR基因不同突变型NSCLC患者疗效及生存率的影响
|
摘要
目的:研究表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)厄洛替尼对EGFR基因不同突变型非小细胞肺癌(NSCLC)患者疗效及生存率的影响。方法:72例EGFR突变阳性的晚期NSCLC患者,根据EGFR基因第19号外显子或第21号外显子突变分为研究组(33例)和对照组(39例),两组患者均口服盐酸厄洛替尼片至病情进展或因肺癌死亡,比较两组患者近期临床有效率、疾病进展时间(TTP)和1年生存率。结果:研究组近期临床有效率、1年存活率、平均TPP均明显高于对照组,组间比较差异具有统计学意义(P<0.05)。结论:使用EGFRTKI厄洛替尼治疗NSCLC患者,EGFR第19号外显子突变患者疗效及生存情况均优于EGFR第21号外显子突变患者,提示检测EGFR基因不同突变位点对制定个体化治疗方案及预测EGFR-TKI厄洛替尼的治疗效果有一定的参考作用。
Objective: To study the effects of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI Erlotinib on curative effects and survival rate of non-small cell lung cancer(NSCLC) patients with different mutants of EGFR gene. Methods: 72 cases of advanced NSCLC patients with EGFR positive mutations were divided into study group(n=33)and control group(n=39) according to mutations in exon 19 or 21 of EGFR gene. All the patients were treated with Erlotinib Hydrochloride Tablets orally till disease progression or death. The short-term clinical effective rate, time to progression(TTP)and one-year survival rate of patients in 2 groups were compared. Results: The short-term clinical effective rate, one-year survival rate and average TTP of patients in study group were all obviously higher than control group(P<0.05). Conclusions:The curative effects and survival rate of NSCLC patients with exon 19 mutation were better than NSCLC patients with exon 21 mutation when treating NSCLC with EGFR-TKI Erlotinib. Which suggests that detection of different mutants of EGFR gene may be helpful in formulating individualized therapeutic regimen and predicting the therapeutic effect of EGFR-TKI Erlotinib.
Objective: To study the effects of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI Erlotinib on curative effects and survival rate of non-small cell lung cancer(NSCLC) patients with different mutants of EGFR gene. Methods: 72 cases of advanced NSCLC patients with EGFR positive mutations were divided into study group(n=33)and control group(n=39) according to mutations in exon 19 or 21 of EGFR gene. All the patients were treated with Erlotinib Hydrochloride Tablets orally till disease progression or death. The short-term clinical effective rate, time to progression(TTP)and one-year survival rate of patients in 2 groups were compared. Results: The short-term clinical effective rate, one-year survival rate and average TTP of patients in study group were all obviously higher than control group(P<0.05). Conclusions:The curative effects and survival rate of NSCLC patients with exon 19 mutation were better than NSCLC patients with exon 21 mutation when treating NSCLC with EGFR-TKI Erlotinib. Which suggests that detection of different mutants of EGFR gene may be helpful in formulating individualized therapeutic regimen and predicting the therapeutic effect of EGFR-TKI Erlotinib.
引文
[1]冯卫能,张华,陈泽程,等.血浆EGFR基因突变检测在晚期非小细胞肺癌患者EGFR-TKI疗效评估中的价值[J].山东医药,2017,57(13):117-119.
[2]肖博文,姚敦武,付滢舟,等.非小细胞肺癌患者厄洛替尼个体化给药研究进展[J].中南药学,2018,16(11):1556-1560.
[3]高雅婷.非小细胞肺癌辨证分型及病理特征与m i R-21/197-3P的相关性研究[D].合肥:安徽中医药大学,2017.
[4]凌止鸿,李月明,陈晶.非小细胞肺癌患者表皮生长因子受体突变对靶向治疗的疗效影响及生存分析[J].实用癌症杂志,2017,32(2):207-209.
[5]魏媛,马新宇,马笛,等.一线EGFR-TKI耐药后接受化疗的晚期非小细胞肺癌患者疗效分析[J].实用医学杂志,2016,32(2):228-231.
[6]张笑雪,臧建华,杨妮霞.外显子19缺失和外显子21L858R突变的NSCLC患者埃克替尼治疗效果比较[J].山东医药,2015,55(37):51-52.
[7]姚晓燕,申淑景,王晔,等.EGFR突变与非小细胞肺癌临床病理和TKI治疗疗效预测相关性分析[J].中华肿瘤防治杂志,2016,23(6):369-372.
[8]姜忠于,胡春秀,刘学武,等.靶向药物治疗对表皮生长因子受体基因不同位点突变的非小细胞肺癌患者预后影响[J].中国临床药理学杂志,2015,31(23):2306-2308.
[2]肖博文,姚敦武,付滢舟,等.非小细胞肺癌患者厄洛替尼个体化给药研究进展[J].中南药学,2018,16(11):1556-1560.
[3]高雅婷.非小细胞肺癌辨证分型及病理特征与m i R-21/197-3P的相关性研究[D].合肥:安徽中医药大学,2017.
[4]凌止鸿,李月明,陈晶.非小细胞肺癌患者表皮生长因子受体突变对靶向治疗的疗效影响及生存分析[J].实用癌症杂志,2017,32(2):207-209.
[5]魏媛,马新宇,马笛,等.一线EGFR-TKI耐药后接受化疗的晚期非小细胞肺癌患者疗效分析[J].实用医学杂志,2016,32(2):228-231.
[6]张笑雪,臧建华,杨妮霞.外显子19缺失和外显子21L858R突变的NSCLC患者埃克替尼治疗效果比较[J].山东医药,2015,55(37):51-52.
[7]姚晓燕,申淑景,王晔,等.EGFR突变与非小细胞肺癌临床病理和TKI治疗疗效预测相关性分析[J].中华肿瘤防治杂志,2016,23(6):369-372.
[8]姜忠于,胡春秀,刘学武,等.靶向药物治疗对表皮生长因子受体基因不同位点突变的非小细胞肺癌患者预后影响[J].中国临床药理学杂志,2015,31(23):2306-2308.